IJCS | Volume 32, Nº5, September/October 2019

523 Table 4 - Clinical and laboratory data by ten-year cardiovascular risk classification (Framingham risk score) in individuals with psychiatric disorders Cardiovascular risk p-value Low (n = 244) Intermediate (n = 41) High (n = 13) Sex Male 108 (88.5) 10 (8.2) 4 (3.3) 0.042* Female 136 (77.3) 31 (17.6) 9 (5.1) Age 40 ± 10.9 55.6 ± 8.76 59.9 ± 8.53 < 0.001** (19 - 75) (24 - 79) (44 - 76) LDL cholesterol 123.6 ± 100 169 ± 105.2 143.5 ± 50.2 < 0.001** (41 - 1324) (97.2 - 608) (67.2 - 241) HDL cholesterol 47.6 ± 14.1 42.7 ± 11.3 37.1 ± 8.06 0.003** (21 - 94) (24 - 85) (26 - 51) Systolic blood pressure 111 ± 14.4 121.7 ± 24.2 118 ± 11.1 0.003** (71 - 175) (85 - 230) (102 - 140) Diastolic blood pressure 73.7 ± 11.2 78.5 ± 9.68 73.3 ± 18.1 0.013* (46 - 131) (57 - 100) (51 - 115) Glycemia 85.9 ± 25.9 101.6 ± 40.8 111.4 ± 26.5 < 0.001** (53 - 274) (46 - 318) (71 - 146) Smoking Yes 196 (65.8) 33 (11.1) 9 (3.0) 0.574 No 48 (16.1) 8 (2.7) 4 (1.3) Chi-square test, Fisher’s exact test, Mann-Whitney test; *Statistically significant at 5%; ** Statistically significant at 1%. Table 5 - Association between metabolic syndrome and moderate or high risk for cardiovascular diseases in patients with mental disorders Intermediate / high cardiovascular risk Classification of MS N (%) p-value OR 95%CI OMS 11(68.8%) < 0.01 12.228 4.047 – 36.951 NCEP 43 (35.0%) < 0.01 8.014 3.924 – 16.367 IDF 43(31.4%) < 0.01 6.238 3.065 – 12.696 MS: metabolic syndrome; WHO: World Health Organization; NCEP: National Cholesterol Education Program; IDF: International Diabetes Federation. Cabral Cardiovascular risk and metabolic syndrome Int J Cardiovasc Sci. 2019;32(5):517-526 Original Article